FIELD: biotechnology.
SUBSTANCE: invention represents a method for obtaining from a parental antibody or antigen-binding antibody fragment, an antibody or antibody fragment, having a condition-dependent binding activity with an antigen, wherein said antibody or antibody fragment comprises at least three CDRs of the parent antibody, providing the ability to recognize and bind the antigen, as well as containing a mutation relative to the parent antibody, wherein said binding activity is measured in the analyzes, conducted at first and second values of said condition, wherein said condition-dependent binding activity depends on both first and second conditions values, at which activity is measured, and also depends on concentration of compound or ion, having molecular weight less than 100 amu, selected from bicarbonate, acetate, lactate, bisulphate, hydrogen sulphide, ammonium, sodium sulphide and any combination thereof.
EFFECT: invention enables efficient production of antibodies.
12 cl, 9 dwg, 4 tbl, 15 ex
Title | Year | Author | Number |
---|---|---|---|
CONDITIONALLY ACTIVE BIOLOGICAL PROTEINS | 2016 |
|
RU2733658C2 |
CONDITIONALLY ACTIVE CHIMERIC ANTIGENIC RECEPTORS FOR MODIFIED T CELLS | 2016 |
|
RU2759957C2 |
CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS | 2015 |
|
RU2764074C2 |
IDENTIFICATION, ASSESSMENT, AND THERAPY OF CANCERS WITH INNATE OR ACQUIRED RESISTANCE TO ALK INHIBITORS | 2011 |
|
RU2589834C2 |
ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY | 2013 |
|
RU2656153C1 |
SPECIFIC BINDING PROTEINS AND APPLICATIONS THEREOF | 2010 |
|
RU2549678C2 |
HETEROMULTIMERS WITH REDUCED OR SILENCED EFFECTOR FUNCTION | 2014 |
|
RU2655439C2 |
ANTIBODIES SPECIFIC TO TUMOUR AND USE THEREOF | 2011 |
|
RU2595403C2 |
MONOCLONAL PD-L1 ANTIBODY | 2017 |
|
RU2665790C1 |
ANTIBODIES AGAINST TENB2 CONSTRUCTED WITH CYSTEINE, AND CONJUGATES, ANTIBODY-DRUG | 2008 |
|
RU2505544C2 |
Authors
Dates
2020-10-27—Published
2016-08-31—Filed